To evaluate immunogenicity consistency between three consecutive batches of commercial-scale productions for Sinovac Rabies vaccine
Participants are able to understand and voluntarily sign the Informed Consent Form;
Able to provide legal identity documents;
Age 18 to 45 years;
Stable health status (defined as stable underlying disease status within 3 months prior to enrollment, i.e., no change in original treatment or hospitalization due to disorder aggravation);
For subjects with pyrexia on the scheduled vaccination day, axillary temperature >37.3℃ before vaccination;
Previous use of anti-Rabies Passive immunization preparations (including but not limited to equine-derived Immunoglobulin ERIG, human-derived Immunoglobulins HRIG, and rabies monoclonal antibody preparations, etc.) or previous Vaccination with human Rabies Vaccine;
Individuals with mammalian animal bites/scratches (e.g., dog/cat) and broken skin (i.e., Category II or higher exposure) within the past year.;
Female participants who are lactating or pregnant (including those with a positive urine pregnancy test).